Ensysce Biosciences (ENSC) EBT Margin (2020 - 2025)
Ensysce Biosciences' (ENSC) quarterly EBT Margin came in at 759.97% in Q3 2025, down 77871.0% year-over-year from N/an in Q3 2024, and down 494.33% quarter-over-quarter from 127.87% in Q2 2025.
Powered by 
Analysis
Ensysce Biosciences (ENSC) EBT Margin (2020 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported EBT Margin for 6 consecutive years, with 759.97% the latest figure, recorded in Q3 2025.
- On a quarterly basis, EBT Margin fell 77871.0% year-over-year to 759.97% in Q3 2025; TTM through Sep 2025 was 246.43%, a 6699.0% decrease from a year earlier, with the FY2024 full-year figure at 153.94%, up 34245.0% from the prior year.
- EBT Margin was 759.97% for Q3 2025 at Ensysce Biosciences, down from 127.87% in the prior quarter.
- Over five years, EBT Margin peaked at 18.74% in Q3 2024 and troughed at 3418.77% in Q2 2022.
- A 5-year average of 783.67% and a median of 623.58% in 2023 frame the typical range for EBT Margin.
- Across the five-year window, EBT Margin sank 312116 bps in 2022 and soared 295107 bps in 2023, its largest moves.
- Over 5 years, EBT Margin stood at 123.48% in 2021, then sank by 253 bps to 436.19% in 2022, then sank by 56 bps to 679.66% in 2023, then soared by 60 bps to 275.17% in 2024, then sank by 176 bps to 759.97% in 2025.
- The last three EBT Margin figures came in at 759.97% (Q3 2025), 127.87% (Q2 2025), and 149.37% (Q1 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 26.66% |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 25.18% |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | -4.11% |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | 29.63% |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | -4.34% |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | 12.17% |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 44.89% |
| 9 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn | 47.58% |
| 10 | Ensysce Biosciences | 1.18 Mn | -3.46 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -759.97% |
| Jun 30, 2025 | -127.87% |
| Mar 31, 2025 | -149.37% |
| Dec 31, 2024 | -275.17% |
| Sep 30, 2024 | 18.74% |
| Jun 30, 2024 | -1,090.78% |
| Mar 31, 2024 | -1,011.06% |
| Dec 31, 2023 | -679.66% |
| Sep 30, 2023 | -623.58% |
| Jun 30, 2023 | -467.70% |
| Mar 31, 2023 | -324.55% |
| Dec 31, 2022 | -436.19% |
| Sep 30, 2022 | -2,208.04% |
| Jun 30, 2022 | -3,418.77% |
| Mar 31, 2022 | -798.85% |
| Dec 31, 2021 | -123.48% |
| Sep 30, 2021 | -1,408.33% |
| Jun 30, 2021 | -297.61% |
| Mar 31, 2021 | -707.52% |
| Dec 31, 2020 | -322.05% |